Systematic literature review and network metaâ€analy inhibitors vs metformin as addâ€on to insulin in type 1

Diabetes, Obesity and Metabolism 22, 39-50

DOI: 10.1111/dom.13863

Citation Report

#	Article	IF	CITATIONS
1	SGLT inhibitors for type 1 diabetes. Practical Diabetes, 2020, 37, 82-85.	0.1	0
2	An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 1799-1803.	0.9	4
3	Costâ€effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes, Obesity and Metabolism, 2020, 22, 1047-1055.	2.2	6
4	Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium–glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020). Diabetic Medicine, 2021, 38, e14458.	1.2	4
5	Demographic characteristics and acute complications among adults with type 1 diabetes: Comparison of two multicentre databases from Germany and the United States. Journal of Diabetes and Its Complications, 2021, 35, 107812.	1.2	3
6	Comparative efficacy and safety of glucoseâ€lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 822-831.	2.2	17
7	Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy. Journal of Diabetes Science and Technology, 2021, 15, 1232-1242.	1.3	7
8	Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose co-transporter inhibitors with insulin for treatment of type 1 diabetes (updated October 2020). British Journal of Diabetes, 2020, 20, 155-162.	0.1	O